SWOG clinical trial number
CTSU/EAE161

Perfusion CT to Predict Progression-free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Closed
Phase
Abbreviated Title
Perfusion CT to Predict PFS and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Status Notes
SWOG Activated/Championed CTSU/EAE161, effective March 1, 2019

Closed to accrual, Effective January 9, 2020.
Activated
03/01/2019
Closed
01/08/2020
Participants
CTSU

Research committees

Early Therapeutics & Rare Cancers

Treatment

Olaparib

Eligibility Criteria Expand/Collapse

Please see the CTSU/EAE161 protocol posted on www.ctsu.org for eligibility criteria.

Other Clinical Trials

SWOG Clinical Trial Number
S1609

DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

Research Committee(s)
Early Therapeutics & Rare Cancers
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Lung Cancer
Melanoma
Activated
01/13/2017
Accrual
88%
Open
Phase
II
SWOG Clinical Trial Number
CTSU/A071401

Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations

Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
01/01/2016
Open
Phase
SWOG Clinical Trial Number
CTSU/EAY131

Molecular Analysis for Therapy Choice (MATCH)

Research Committee(s)
Early Therapeutics & Rare Cancers
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Lung Cancer
Lymphoma
Melanoma
Myeloma
Activated
07/15/2015
Open
Phase